On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

Wolfe Research initiated coverage of AbbVie (ABBV) with an Outperform rating and $205 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.

Multiple sclerosis (MS) is a chronic neurological disorder affecting the central nervous system (CNS), particularly the brain, spinal cord, and optic nerves. Continuous research has led to new drug ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

Continuity Biosciences, LLC, a new bioscience company dedicated to developing and commercializing cutting-edge technologies ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

The pharma is trying to win court backing to pay hospitals rebates for two drugs in the 340B drug discount program, instead ...

Brian Skorney has given his Buy rating due to a combination of factors including the recent failure of AbbVie’s emraclidine in Phase ... Inc. operates as a product based bio-pharmaceutical company. It ...

AbbVie’s stock price fell over 12% after emraclidine, an investigational anti-psychotic being evaluated for the treatment of ...

In May 2024, GSK announced positive headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and ...

November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024 Highlights European Commission (EC) granted conditional marketing authorization for TEPKINLY® (e ...